Surveillance of women with a personal history of breast cancer by tumour subtype.
OBJECTIVE
To determine if the rate and timing of a second breast cancer event (SBCE) in women with a personal history of breast cancer varies by disease subtype or breast imaging method.


METHODS
A retrospective review was performed of women with a SBCE from January 2006 to December 2010 at a single institution. Data analysed included oestrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2) status of the primary and second breast cancers; mammographic and ultrasound (US) features from SBCE; and the time interval between both events.


RESULTS
Of 207 patients diagnosed with a SBCE, the median age at first diagnosis was 50.6 years, range 24.8 to 80.2; at second diagnosis was 56.2 years, range 25.8 to 87.9. Eleven percent of SBCE were diagnosed >10 years after the primary cancer diagnosis. The median time between the first and second diagnosis for ER-positive patients was 2.7 years (range 0.7-17.4 years); and 1.9 years for ER-negative patients, (range 0.4-23.4 years; p<0.002). Patients with triple-negative breast cancer (TNBC) had a shorter time between diagnoses than others (p=0.0003). At 3, 5, and 10 years, 85%, 92%, and 97% of ER-negative and 54%, 81%, and 95% of ER-positive tumours, respectively, had recurred. ER-negative tumours and TNBC were more likely to be visible at US.


CONCLUSIONS
There may be a role for customised imaging surveillance of women with a personal history of breast cancer (PHBC) after 10 years. Further studies are necessary to determine if US may be valuable in the surveillance of patients with ER-negative and TNBC tumours.
Departments of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA. Electronic address: anapaula.atihe@gmail.com.
A P
AP
Benveniste
Departments of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
M J
MJ
Dryden
Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
I
I
Bedrosian
Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
P K
PK
Morrow
Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
R L
RL
Bassett
Departments of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
W
W
Yang
D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D001940:Breast / Q000000981:diagnostic imaging; D001943:Breast Neoplasms / Q000097:blood / Q000000981:diagnostic imaging*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008327:Mammography / Q000379:methods*; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000000981:diagnostic imaging*; D011159:Population Surveillance; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000097:blood; D011960:Receptors, Estrogen / Q000097:blood; D011980:Receptors, Progesterone / Q000097:blood; D015203:Reproducibility of Results; D012189:Retrospective Studies; D064726:Triple Negative Breast Neoplasms / Q000000981:diagnostic imaging; D016217:Ultrasonography, Mammary / Q000379:methods; D055815:Young Adult
D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone